As examples, PML opposes tumorigenesis in acute promyelocytic leukemia (APL), the disease where it was originally identified (de Thé et al, 2017), and solid tumors like prostate and lung cancer (Chen et al, 2018; Wang et al, 2017), but holds oncogenic activities in triple-negative breast cancer (TNBC) (Carracedo et al, 2012; Martín-Martín et al, 2016; Ponente et al, 2017; Arreal et al, 2020), ovarian cancer (Gentric et al, 2019; Liu et al, 2017), and glioma (Amodeo et al, 2017; Aldaz et al, 2022; Kuwayama et al, 2009; Iwanami et al, 2013; Tampakaki et al, 2021). The gene discussed is PML; the disease is ovarian carcinoma.